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MR guided radiotherapy represents one of the most promising recent technological
innovations in the field. The possibility to better visualize therapy volumes, coupled with the
innovative online adaptive radiotherapy and motion management approaches, paves the
way to more efficient treatment delivery and may be translated in better clinical outcomes
both in terms of response and reduced toxicity. The aim of this review is to present the
existing evidence about MRgRT applications for liver malignancies, discussing the
potential clinical advantages and the current pitfalls of this new technology.
Keywords: magnetic resonance guided radiotherapy, stereotactic body radiation therapy, image guided radiation
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INTRODUCTION
The recent introduction of integrated magnetic resonance (MR) linear accelerators (linacs) into
clinical practice has opened new perspectives for radiation therapy (RT), offering the advantages of
coupling 0.35 or 1.5 T on-board MR scanners firstly with a triplet of 60Co heads and later with 6 and
7 MV linacs in stand-alone hybrid units (1–3). MR guided radiotherapy (MRgRT) has been
successfully applied to several anatomical sites, exploiting online adaptive planning solutions and
innovative motion management, with improved dosimetric performance and early clinical results
suggesting improved efficacy and toxicity reduction (4–6). Despite the numerous explored
applications, the published clinical evidence is still scarce, and the actual quantification of the
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advantages of using such an advanced technology is still the
object of debate in the radiation oncology community (7). The
types of cancers generally considered most suitable for MRgRT
are those located in anatomical sites where similar levels of tissue
density in computed tomography (CT) imaging do not allow a
precise identification of the different therapy volumes, especially
if they are movable and particularly close to radiosensitive organs
at risk (OAR).
In this framework, liver malignancies appear to be ideal for
MRgRT applications for several reasons, especially when
considering the growing role that stereotactic body radiation
therapy (SBRT) is gaining in the treatment of both primary liver
tumors or liver metastases (8–10). MRgRT could indeed be a
competitive option to improve tumor control, especially during
hypofractionated radiotherapy and for tumors that are poorly
visualized on standard radiotherapy CT imaging (i.e. liver
cancers). Furthermore, the innovative online adaptive solutions
have made it possible to dose escalate to ablative doses even for
targets close to sensitive OARs (e.g. bowel loops, duodenum,
stomach) (4, 8, 11–13).
The aim of this article is to describe the state of the art of
MRgRT for liver tumors, focusing on the most promising liver
cancer clinical indications, the role of the different MRI
sequences provided by the hybrid scanners, and the advantages
of applying motion management and advanced adaptive
approaches using MRgRT.
LIVER MRgRT CLINICAL INDICATIONS
The role of RT in the management of primary and secondary
liver tumors has substantially increased over the years. Emerging
data suggest local treatment benefit for both hepatocellular
carcinoma (HCC) and oligometastatic disease, integrating
radiation therapy (RT) in different ways with available
systemic and local therapies (14). In both the aforementioned
disease conditions, the treatment of choice is surgery with 5-
years survival rates of 30–60% for colorectal cancer (CRC) liver
metastases and 50% for HCC, with 4-years survival of 74% after
liver transplantation (15–17). Other liver-directed treatments,
such as radiofrequency ablation (RFA), interstitial brachytherapy
(IBT), microwave ablation (MWA), or percutaneous ethanol
injection (PEI) are valid treatment options for small tumors
when surgery is not possible, e.g. due to comorbidities or limited
liver reserve (17). Transarterial chemoembolization (TACE),
Yttrium-90 (90Y) transarterial radioembolization, and drug-
eluting bead transarterial chemoembolization (DEB-TACE) are
regional, non-curative therapies used to improve survival in
selected HCC patients (18, 19). Many patients with liver
cancers are not well suited for these local–regional therapies,
and many others develop recurrences despite the use of these
therapies. Thus there is a potential role for RT to be used to treat
these patients who may not be treated with ablative therapies
otherwise. Liver radiotherapy has been historically used for
palliation, but its therapeutic paradigm is changing, in part due
to the application of SBRT which allows a high conformation of
the dose to the target with efficacious sparing of the OARs and
significant reduction of the risk of radiation-induced liver disease
(RILD), which represents an important cause of comorbidity,
especially for primary liver cancers (20).
Primary Liver Lesions
Numerous trials have demonstrated the effectiveness of SBRT in
primary liver cancers, but there is still no conclusive scientific
evidence to definitely determine the role and benefits of RT in
this setting (21, 22). SBRT plays a major role mainly when
surgery or other local ablative procedures (e.g. RFA) are
contraindicated or high risk. Such patients may have early
stage tumors with a high chance of sustained local control, e.g.
HCC early stage by the Barcelona Clinic Liver Cancer (BCLC)
classification: solitary lesions ≤5 cm in maximum diameter or
multiple nodules (≤3 total) measuring ≤3 cm in maximum
diameter, absence of vascular invasion and extra hepatic
metastasis (23). SBRT can also be used as a salvage treatment
after other local therapies have failed (23). Alternatively, SBRT
has an increasing role in intermediate and advanced stage
tumors, where avoiding toxicity is important.
The feasibility and effectiveness of SBRT have been
demonstrated in comparative studies between SBRT and RFA
and between SBRT in combination with TACE versus SBRT
alone, without negative impact on the toxicity profile (24–26).
Particular caution should be used for patients with more
impaired liver function, e.g. Child Pugh score >8 points,
reserving SBRT only as a bridge to transplantation, since a
correlation with increased liver toxicity has been reported in
these patients subset (27–29).
Encouraging results of SBRT on survival and toxicity have
also been reported in patients where TACE and surgery are
contraindicated due to the presence of portal vein tumor
thrombosis (PVTT) (30, 31). Small series have reported results
following the combination of SBRT with Sorafenib, a multikinase
inhibitor targeting the Raf/MEK/ERK pathway, and caution is
suggested in this subset of patients due to the possible increase of
hepatic toxicity for possible post irradiation impairment of
normal tissue recovery process secondary to anti VEGF activity
(32–34).
Immunotherapy, in particular, therapies targeting PD-L1-
PD-1 pathways (i.e. checkpoint inhibitors, Atezolizumab) and
antibodies targeting vascular endothelial growth factor (VEGF),
is taking on an emerging role. The combination of atezolizumab
and bevacizumab has been shown to result in better OS and PFS
outcomes than Sorafenib in patients with unresectable HCC (35).
Lastly, even if not supported by robust evidence, some
published experiences also suggest a potential role for SBRT
also in the management of cholangiocarcinoma, especially when
combined with systemic therapies (36).
Liver Secondary Lesions
SBRT plays an important role also in the management of non-
resectable oligometastatic liver disease, and several studies have
demonstrated the role and effectiveness of SBRT as a non-
invasive, well-tolerated, and promising therapeutic approach,
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especially in the light of the aforementioned technological
progress represented by MRgRT.
Hypofractionated regimens have been adopted for some time
now, showing promising results on local disease control, but the
potential for unnecessary high dose OAR irradiation, linked to
increased rates of toxicity, has limited widespread use of SBRT
(37–40). The optimization of traditional SBRT delivery
technologies (i.e. Cone beam CT, CBCT, IGRT protocols, and
fiducial based irradiation) has achieved better local control rates
for small lesions, reporting local control rates >90% when doses
of 46–52 Gy are delivered in three fractions for unresectable
colorectal metastases (41, 42). Dose escalation appears therefore
to be directly linked to local control and clinical outcomes, and
MRgRT may ensure higher degrees of safety and efficacy.
Multidisciplinary assessment is recommended to identify
patients who may be eligible for SBRT, based on location, size,
and morphology of liver lesions and on patient performance
status, liver function, and residual healthy liver volume (42).
Careful selection of patients for ablative therapies is required
when there is a potential risk of RILD or when patients have
comorbidities that contraindicate invasive treatments. SBRT can
be used for metastatic lesions that are challenging to be treated
with RFA due to their proximity to critical structures (e.g.
subcapsular, periampullary, perihilar or when adjacent to
vascular structures). An advantage was shown in terms of 1-
year freedom from local progression (FFLP) when SBRT is
compared to MWA when larger lesions are treated (43, 44).
Furthermore, recent data encourage the use of RFA and SBRT
for the management of multiple liver metastases (45).
Clinical MRgRT Liver Evidence
Rosenberg et al. (11) and Feldman et al. (46) have focused on
the feasibility of MRgRT in the treatment of both primary and
secondary hepatic neoplasms. Rosenberg et al. (11) analyzed
the outcomes of 26 patients treated with MRgRT SBRT
technique in different institutions. Patients with both Child–
Pugh A or early B and presenting one to three liver lesions
were included. Median PTV was 98.2 cc (13–2,034), with a
median delivered dose of 50 Gy in five fractions, and median
liver dose of 12.7 Gy (3.2–21.9). The applied gating protocols
were deep inspiration breath hold (DIBH) (16 patients) and
modified shallow internal target volume or exhale-based setup
for treatment (10 patients), depending on the patient’s
compliance. At 21 months follow-up, local control rate was
80.4% with grade 3 gastrointestinal toxicity found in two
patients (7.7%, with one case of portal hypertension and one
of hilar stricture requiring procedures) who had a large
treatment volume and had undergone previous liver-
directed treatments. The 1-year and 2-years OS were 69 and
60% respectively.
In the cohort of 29 patients treated by Feldman et al. (46), 26
were affected by HCC, two by cholangiocarcinoma, and one
presented liver metastases. A total of 31 lesions were treated with
a dose ranging from 45 to 50 Gy in five fractions, while the
remaining three were treated with doses from 27 to 42 Gy in
three fractions. The mean liver dose was 5.56 Gy (1.39–10.43).
Motion was managed by treating 21 patients in end-exhale, six in
end-inhale, and two in free breathing conditions. One patient
was also treated with adaptive technique. Patients were
monitored in follow-up from one to 12 months post-
treatment, showing either stable or decreased size of all but
one treated lesion. The highest observed toxicity was grade G2
with a case of nausea and vomiting and a case of abdominal pain
with melena that did not require pharmacological intervention,
but only a brief interruption of treatment.
Moreover, Henke et al. (47) reported the potential of the
Stereotactic MR-guided adaptive radiation therapy (SMART)
approach (48) in a cohort of oligometastatic patients including
11 patients affected by secondary liver lesions and four with
HCC. At median follow-up of 15 months only two patients with
recurrent locally advanced pancreatic cancer underwent local
progression. No grade 3 toxicity has been observed in this cohort
of patients, while 6-months local progression free survival rate
and 1-year OS were of 89.1 and 75% respectively. Hal et al. (49)
recently presented data from a cohort of 10 patients affected by
upper abdominal neoplasms (of whom four were affected by
secondary liver lesions and two by HCC), treated with 1.5 T
MR-linac.
HCC patients received 40–45 Gy in five fractions, while those
with metastatic lesions 45–60 Gy in three fractions or 50 Gy in
five fractions. A 4DCT and a 4DMRI with IV contrast agent were
acquired in the simulation phase.
Motion was managed creating an ITV from the 4DCT
simulation. Treatment has been carried out with both adapt-
to-position (ATP) and adapt-to-shape (ATS) approaches, and
the delivery has been performed with a real-time cine MRI
acquired in three perpendicular planes. At 7.2 months follow-
up, two patients developed G2 skin toxicity, and no local
recurrences or progression of the treated lesions was recorded.
The feasibility and patients’ acceptability of MRgRT were
investigated in a prospective study that enrolled 43 patients,
including eight with liver lesions, who underwent respiratory-
gated treatments in DIBH, of which 47% SBRT (50). The
treatment was carried out with visual guidance of the live
sagittal low T cine-MRI during gated delivery coupled with
audio feedback when necessary. Patients compiled an in-house
developed patient-reported outcome questionnaire to document
their treatment experience and tolerance. Although 65% of
patients reported some MR-related complaints (e.g.
paraesthesia, uncomfortable positioning), MRgRT was overall
defined as positive or at least tolerable.
All patients reported high levels of satisfaction related to their
active participation in treatment. No acute toxicity ≥G2 was
recorded in the entire cohort, except for four patients reporting
G2 fatigue.
Table 1 summarizes some of the clinical studies on the use of
MRgRT in the treatment of hepatic malignancies.
MRI IMAGING CHARACTERIZATION
The reliable identification of liver lesions on hybrid MR imaging
depends on several issues and has direct consequences in RT
treatment planning (i.e. planning target volume, PTV, margin
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definition, and gating solutions). Magnetic resonance scanner
field strength, presence of image artefacts (especially respiratory
related ones), used sequence, and the administration of contrast
agents should be considered among the technical ones. Other
clinical and patient’s specific parameters have specific
consequences on image quality and reliability for radiotherapy
segmentation and planning purposes, such as the kind of disease
(primary liver tumors or secondary lesions), the involved hepatic
segment or specific anatomical conditions. MR-linacs currently
allow the acquisition of a default sequence which is similar to the
standard “true-FISP”, both in the 0.35 and 1.5 T clinical
solutions. This sequence generally allows tumor identification
and easier segmentation of the upper abdominal OAR,
representing an advantage when compared to kV CBCTs (55).
Favorable experiences regarding the visibility of metastases and
primary liver cancer have been reported for both low and high
field MR-linac hybrid devices (46, 49). Furthermore, the use of
contrast agents or specific sequences enriches the standard
positioning image and allows better visualization of the OAR.
Liver specific contrast agents such as gadoxetic acid (i.e. Gd-
EOB-DTPA or Gd-BOPTA) are eliminated through the biliary
tract and lead to a bright appearance of the liver, therefore
improving the contrast between healthy and tumorous liver
tissue and offering a better visualization and characterization of
the lesions in late hepato-specific phase (56). Such agents have
also been used in the context of clinical online MRgRT; however,
caution is warranted with the repeated application of contrast
agents within a short time frame, and safety data are still scarce
about possible toxicity. When clinically indicated, MR
compatible fiducials may also be implanted as reference
markers: platinum ones have the most favorable technical and
logistic profile (57). Imaging and sequence comparison studies
between diagnostic and hybrid MRI are still lacking, and the
need to rely on standard diagnostic imaging, especially for target
volume segmentation support, is currently still strongly
suggested for MRgRT applications.
Primary Liver Cancers
HCC nodules show great variability in imaging characteristics
and radiological aspects due to the varying content of substances.
Their semeiotics in T1WI and T2WI is generally not constant,
and the acquisition of dynamic contrast is a key factor for
diagnosis and tumor characterization, especially to detect
vascular invasion (58).
HCC usually shows early arterial phase enhancement and
rapid washout in the portal venous (PVP) or delayed phases
(DP), while it is generally hypointense in the hepatobiliary phase
(HBP) (59). The use of T2WI and DWI may be useful to make
differential diagnosis between uncommon hyperintense HCC
presentations or focal nodular hyperplasia or other benign
conditions. The semeiotics of HCC nodules in standard 0.35 T
TRUFI imaging is mixed with prevalence of hyper-isointense
aspect. Figure 1 shows HCC lesions on hybrid MRgRT images
for both high and low tesla units.
The radiological aspect of cholangiocarcinoma on
MR imaging depends on the anatomical site and on its
growth characteristics and may be successfully described
using complex magnetic resonance studies including
cholangiopancreatography, conventional T1WI, T2WI, DWI,
and Dynamic Contrast Enhanced (DCE) sequences. Peripheral
mass-forming intrahepatic presentations generally appear
isointense or moderately hypointense in T1WI and
hyperintense in T2WI, with restricted diffusion in DWI.
Contrast enhancement is characteristically late and centripetal
and may facilitate the differential diagnosis from other masses
(i.e. HCC and metastases). Periductal infiltrating lesions are
visible on T2WI showing hyperintense dilatation of the
upstream ducts, while extrahepatic ductal forms generally
TABLE 1 | Recent clinical studies on the role of MRgRT in hepatic malignancies.
Reference year dose Patients (n) Response






Feldman et al. (46) 2019 45 to 50 Gy/5 fractions 26 HCC
2 cholangiocarcinoma
6 MLL
1 year LC 96.5%
1 year OS 92.8%

















Boldrini et al. (53) 2021 Median dose of 50 (50–55) Gy
in 5 fractions





50–60 Gy in 5 to 6 fractions 46 Primary or secondary liver
tumor(s)
2 years LC
Lack of progression according to RECIST
criteria
MLL, metastatic liver lesions; OS, overall survival; LC, local control; LPFS, local progression free survival.
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appear as masses to be differentiated from pancreatic head
adenocarcinomas (60). Cholangiocarcinomas are generally
hypointense in TRUFI on 0.35 T hybrid units.
Secondary Lesions
Liver metastases are generally hypointense in the HBP, appearing
as areas of loss of signal with respect to the enhanced normal
liver parenchyma, due to cellular substitution (61). The
radiological semiotics of secondary hepatic lesions may suggest
the originating disease, thanks to specific image characteristics.
Adenocarcinomas metastases appear hypointense in T1WI,
slightly hyperintense in T2WI, with restricted diffusion and
low apparent diffusion coefficient (ADC) values. The use of
contrast agents generally discloses a hypovascularized central
core accompanied by a hypervascularized external rim (62, 63).
Pronounced hypervascularization in dynamic phases is
characteristic also of neuroendocrine tumors (NETs);
melanoma, thyroid, and renal cancer more often show a
hypervascularized aspect (64–66). On the other hand,
colorectal, lung, and breast cancer secondarisms generally
appear hypointense compared to the enhancing normal liver
parenchyma in PVP. Secondary liver lesions generally appear as
hypo-isointense nodules in standard 0.35 T TRUFI positioning
image (see Figure 2) (63).
Table 2 summarizes the sequences of more common clinical
use for liver target volumes identification.
MRI BASED RT VOLUME SEGMENTATION
The standardized and accurate definition of target volumes and
OAR has become an even more crucial factor in the MRgRT
workflow. For instance a relevant organ at risk delineated
erroneously too large might prevent sufficient target volume
coverage in the daily adaptive workflow and, vice versa, severe
toxicity may result if OARs are not delineated at their full extent.
FIGURE 1 | HCC nodules on T2 weighted 1.5 T hybrid imaging (left) and on T1 weighted 0.35 T hybrid imaging (right).
FIGURE 2 | Liver secondary lesions on T2 weighted 1.5 T hybrid imaging (left, hyperintense, from breast cancer) and on T1 weighted 0.35 T hybrid imaging (right,
hypointense, from gastric cancer).
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For this reason, a panel of radiation oncologists and radiologists
with experience in the field of online MR guided radiotherapy of
the liver has recently published an atlas for OAR contouring in
the upper abdomen (55). Dicom datasets with recommended
delineations of upper abdominal OAR structures can be found at
www.econtour.org. More specifically, when contouring the liver
on MRI it is recommended to exclude the inferior vena cava and
include the caudate lobe in order to achieve an appropriate
quantification of functional liver tissue. Both structures are
challenging to identify on non-contrast enhanced computed
tomography simulation scans but can well be visualized on
both T1WI and T2WI. Another structure that is sometimes
poorly visible on CT scans is the common bile duct. Post hoc
studies of hepatobiliary toxicities, such as biliary structures or
elevated liver function tests after SBRT for centrally located
tumors, suggest a dose effect for these toxicities (67). The
common bile duct can be clearly seen on T2WI in most cases
or on the HBP after the application of liver specific contrast
agents. The delineation of this structure might help to prevent
these toxicities by considering them during plan adaption and to
further improve our knowledge about the dose–volume
relationship in this anatomical site (68). Stomach, duodenum,
and small bowel loops are the most critical OAR when high doses
of radiotherapy are applied in the upper abdomen. In most
instances a T2 weighted scan is the optimal sequence for their
delineation; however due to motion artifacts caused by peristalsis
there is still a need for optimized sequences in adaptive MR-linac
workflows and OAR margin definition indications. The
administration of a glass of water shortly before the treatment
fraction may help in visualizing the stomach and the duodenum
(that will appear hyperintense in TRUFI and T2 images), while
the use of antiperistaltic agents (e.g. butylscopolamine) may
reduce the motion related artefacts allowing a more efficient
and reliable segmentation process.
MOTION MANAGEMENT FOR
LIVER MRgRT
SBRT is characterized by the attempt to minimize PTV and to
provide a rapid dose fall off towards the surrounding healthy
tissues. Especially in liver SBRT, the main challenges are the
proximity of the tumor to many vulnerable OARs such as the
healthy liver, duodenum, stomach, bowel, kidneys, or spinal cord
and the mobility of both the tumor and the surrounding OARs
triggered by breathing-related motion or by changes in the filling
status , anatomical arrangement or deformation of
gastrointestinal organs (69). Organ motion in the abdominal
region is greater than in other sites, with movements in the
cranio-caudal direction of up to 4 cm, which is two to three times
larger than the movements in the anterio-posterior or lateral
directions (69, 70). This is often compensated by an increase in
the irradiated internal target volume (ITV concept) (71), which
on the other hand can be accompanied by the trade-offs of losing
the potential gain of modern radiation techniques in sparing
OARs. In liver radiotherapy, the post-interventional liver
function can be predictive for patient survival (72). Therefore,
adherence to radiation tolerance of normal liver tissue and
keeping the associated risk of RILD to a minimum are of
utmost importance.
Available motion management strategies to compensate for
intrafractional breathing-related organ motion in conventional
image-guided liver SBRT can be categorized into: 1) non-gated
techniques (with or without mechanical abdominal
compression) using the adoption of the ITV or mid-position
concept; 2) respiratory-gated techniques, including use of a
breath-hold ‘immobilization’ approach; or 3) real-time tumor
tracking (73, 74). Due to the relatively poor soft tissue contrast in
conventional SBRT using CBCT, frequently the tumor cannot be
directly visualized, and implantation of fiducial markers next to
the tumor or other surrogates is needed to facilitate image-
guidance (75, 76).
In this setting, the application of MRgRTmarks the beginning
of a new era, as multiple features of this new technology may
improve the application of liver SBRT and enable dose escalation
strategies, and reduced doses to adjacent normal tissues. Besides
the advantages of online treatment plan adaption strategies,
which will be highlighted in the next section, the technology
enables a direct visualization of the target—even during
treatment delivery (4, 77). With currently available MR-linac
systems, continuous real-time 2D-cine-MRI is used to assess
tumor motion (2, 78). In future, also three-dimensional (3D) MR
scans at an adequate resolution and frame rate to monitor fast
motion might be available and further improve the applicability
of MR guidance for intrafractional motion monitoring (i.e. 4D or
respiratory correlated MR) (73). To date, the Viewray system
also allows automated gating by using repeated fast planar cine-
MRI in a sagittal plane with four to eight frames per second (2).
This eliminates the need for invasive implantation of fiducial
markers as well as the application of ITV in order to account for
intrafractional motion (50).
Early experiences show promising results (8, 11, 46).
Rosenberg et al. (11) report on a multi-institutional experience
of MR-guided SBRT using a 0.35 T MR-linac system.
Respiratory-gated SBRT was performed by using a voluntary
breath-hold procedure without any external respiratory motion
management system. Simulation with real-time sagittal TRUFI
cine MRI sequences was used to evaluate tumor motion and to
find a reproducible and tolerable breath-hold level. The breath-
hold technique requires that the patient inhales to a specified
threshold and successively holds the breath at a specific level of
inspiration during delivery of every radiation beam. This enables
minimization of tumor movement and allows for a reduction of
the irradiated liver volume. While the breath-hold technique is
TABLE 2 | Liver lesions in the different MR sequences in current MRgRT clinical use.
Lesion T1WI (non-CE) T2WI TRUFI (0.35 T)
Hepatocarcinoma Hypointense Iso-hyperintense Iso-hyperintense
Cholangiocarcinoma Hypointense Iso-hyperintense Iso-hypointense
Metastases Hypointense Hyperintense Hypointense
CE, contrast enhanced.
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usually performed in deep inspiration for thoracic tumors, a
shallow breath-hold or expiration breath-hold seems also feasible
to mitigate target movement for upper abdominal tumors, like
liver tumors. In this setting, the breath-hold technique has
proven to be a safe and effective way to reduce tumor motion,
resulting in an average intrafractional movement of <1 mm in all
directions and an average cranio-caudal interfractional
reproducibility of <4 mm (79, 80). Some authors reported on
the implementation of an additional visual feedback for the
breath-hold procedure using in-room screens or projectors (81,
82). This allows patients to see their live cine MR images
including projections of target and gating boundary and, thus
actively control their breathing.
During RT delivery, the 0.3 T MR-linac system can
automatically gate the beam by using real-time anatomy
structure tracking (83). For this purpose, a target structure is
defined in the sagittal view of the volumetric MRI, and a
surrounding gating boundary contour is created by adding an
appropriate tracking margin. Usually, the gating boundary is
equal to or less than the PTV margin. The tracking algorithm
deforms the anatomical contour on every subsequent live cine
MRI frame and compares it to the static boundary contour. If the
anatomy of interest moves outside the boundary, the beam is
stopped until the tracked anatomy returns into the boundary.
The percentage of the target that may be outside the boundary
before beam is shut-off can individually be adjusted. The vendor-
defined specification for the gating latency of the 0.3 T MR-linac
system is <500 ms (2).
The target structure used for tracking is usually the liver
tumor itself. Nevertheless, some liver tumors are often poorly
visualized, even in MR imaging. Therefore, the application of
hepatocyte-specific contrast agents, such as gadoxetate disodium,
is reported to significantly improve visualization of liver lesions
during simulation and real-time MR-guided SBRT (84). If
visualization is still not optimal, tracking can also be
performed on surrogate structures, such as the portal vein,
liver contour, or other anatomical structures (11). The Unity
system is likely to have this capability soon, but at present can
only gate the beam manually.
Taken together, MRgRT using a respiratory-gated SBRT with
a breath-hold technique enables a completely non-invasive
approach to treat liver lesions while reducing the irradiated
volume of the uninvolved healthy liver tissue. Furthermore, the
ability of MR-linac systems to provide direct visualization of the
patient anatomy throughout the treatment fraction can also
reduce interfractional and intrafractional uncertainties in target
localization and allow dose escalation strategies (85).
ADAPTIVE APPROACHES FOR
LIVER MRgRT
Adaptive radiotherapy (ART) emerged in the radiation therapy
lexicon over 20 years ago, initially signifying a means to control
daily set-up error using megavoltage portal imaging (86).
However, the term now broadly signifies the process by
which the delivered dose is monitored and modified during
the course of treatment to ensure clinical acceptability and
maximize clinical outcomes. Online ART specifically refers to
the daily modification of the radiation treatment plan in
response to observed changes in daily tumor and/or OARs
anatomy, while the patient remains on the treatment table. This
may adjust for tumor response (87) or inter-fraction tumor/
OAR motion (51) and has the intent of maximizing the
therapeutic index.
Online ART thus depends on high quality on-board imaging
that is sufficient to visualize and delineate the target and/or OARs
for daily plan re-optimization. Logically then, the clinical
implementation of integrated MRgRT and MRI-guided online
ART (MRgART) in 2014 (87) has led to the rapid expansion in
use of online ART, including for liver tumors. MR-guided online
adaptive radiotherapy can have several advantages over
conventionally planned radiotherapy. The most established of
these include target dose escalation, OAR dose reduction, and
plan adjustment based on target response to treatment. Online
adaptation through MRgART can allow target dose escalation
and OAR dose reduction due to improved management of
unpredictable inter-fraction motion. For patients with tumors
near dynamic OARs, inter-fraction changes historically lead to
uncertainty in the daily tumor/OAR geometric relationship.
These uncertainties limit dose in order to maintain safety. In
the upper abdomen, stomach filling, duodenal distension and
motion, and small and large bowel motion may all lead to large
changes in the proximity of liver targets to OARs (88). Online
adaptation allows for daily plan adjustment in response to these
changes to spare OAR dose while enabling confident delivery of
ablative tumor dosing.
MRgART also enables plan changes to account for more
predictable changes, such as tumor response over the course of
therapy, or patient factors like weight loss or gain. However, it
should be noted that given the additional time, personnel, and
resources required to adapt a treatment plan at up to each
fraction (89, 90), the tendency over the past six years of use has
been implementation of MRgART mainly for SBRT or similarly
hypo-fractionated courses, rather than for adaption for
predictable changes occurring over a longer fractionation (91,
92). Thus, inter-fraction changes like day-to-day OAR motion
are the more common driver of online adaptation in the current
era, and most current data and experience with upper
abdominal and liver MRgART is in this setting. As
technology improves and time of delivery of MRgART
shortens, use of MRgART may be more common in
conventional fractionation schemas.
Given these specific advantages as well as the resources
required for MRgART, patient selection is an important aspect
of MRgART. With regard to the advantage of accounting for
changing tumor/OAR geometry, tumors within 2 cm of the
viscous gastrointestinal tract (i.e. peripheral liver tumors) are
more likely to require plan adaptation than tumors surrounded
by normal liver parenchyma (51, 52). This is due to the rapid
dose fall-off with SBRT planning, wherein inter-fraction OAR
motion has to occur within the higher dose gradients in order to
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meaningfully affect potential OAR dose. This may be particularly
important in patients with liver metastases, where dose
escalation has been linked with improved local control (93).
While HCCmay be successfully treated at somewhat lower SBRT
doses, nearer to point dose tolerances of the stomach and bowel
(94), large changes in stomach and OAR filling can be observed
that exceed reasonable planning OAR volume (PRV)
construction for avoidance (88). Therefore, peripheral HCCs
may benefit from online adaptation to maintain adequate tumor
dose while minimizing risk to OARs.
Other primary liver cancers, like cholangiocarcinomas, may
also benefit from daily plan adaptation in order to mitigate
potential OAR injury. This adaptation, which may in turn allow
for safe tumor dose escalation, has been correlated with
improved overall survival in cholangiocarcinoma patients (95).
This style of dose escalation requires less intentional,
conservative underdosing of the tumor rind adjacent to OARs
and could be performed instead of the conventionally
fractionated, multiple dose level, PRV approach that many
centers use to attempt tumor dose escalation while protecting
OARs. Similarly, in hilar cholangiocarcinomas, MRgART has
been shown to minimize dose to the stomach and duodenum
that can otherwise occur from daily changes in stomach and
duodenal distension and positioning (52). This may allow further
dose escalation in this challenging location, which may improve
local control, a key element of either definitive or bridge-to-
transplant therapy in these patients. Higher dose delivery may be
feasible here, as the common bile duct (CBD) is often
permanently stented in these patients, which may mitigate long
term biliary stenosis (96), or can alternatively be in the setting of
daily monitoring of dose to uninvolved duct, as the CBD is well-
visualized on both 1.5 and 0.35 T on-board images (55).
MRgART also requires new considerations in workflow,
which can be separated into: 1. Simulation, 2. On-table pre-
treatment, and 3. Beam-on time-frames. At the time of this
writing, there are two commercial integrated MRgRT platforms
capable of online ART: the Elekta Unity 1.5 T device and the
ViewRay MRIdian 0.35 T system. For simulation, computed
tomography imaging is typically still obtained for density
information for initial and subsequent adaptive plans. Patients
can then be additionally imaged on the treatment MR-linac,
which is helpful to learn how well target and OAR anatomy will
be visualized ahead of the on-the-fly portion of adaptive re-
planning. Standard immobilization can be used (as long as
devices are MRI compatible), which can also help to minimize
the need to online adapt simply to adjust for gross positional
changes. Reproducibility of imaging coil positioning should also
be considered, with options like building the coils into
immobilization devices or custom table-overlays used variably
between institutions.
In contrast to CBCT based IGRT, patients typically do not
require fiducials, as the tumor is well-visualized on the available
sequences of both devices. Intravenous contrast hepatobiliary
contrast agents can be used for simulation and have also been
shown to be safe for daily use in the setting of SBRT fractionation
in patients with adequate renal function (84). Acquisition of
simulation images both with and without contrast can help
identify the cases in which it will be necessary for daily online
ART fractions and, conversely, spare its daily use in those cases
where it is less impactful.
The two commercial platforms share a similarly structured,
on-table adaptive workflow, with minor differences (97). Of note,
the 1.5 T system has two “adaptive” workflows, an “adapt to
shape” workflow, which is akin to the definition of online
adaptation used in this writing and used on the 0.35 T system,
and an “adapt to position” workflow. The “adapt to position”
workflow is essentially an isocenter shift (via a shift in MLCs) to
overcome the inability to shift the patient couch on the 1.5 T
system and is not the focus here.
On each platform, the on-table component of MRgART
fractions is initiated by acquisition of the daily, online
volumetric MRI. Typically, this sequence will match the
sequence used at simulation to minimize impact of imaging
differences on perceived changes in anatomy-of-the-day. Next,
the pre-treatment planning image is rigidly registered to the
image of the day, generally to the centroid of the gross liver
tumor volume, or to adjacent surrogate structures if the tumor is
difficult to visualize (vascular structures, liver edge, etc). On the
1.5 T system, this is achieved through export to a separate
treatment planning system (TPS Monaco) (98). On the 0.35 T
system, this is on the dedicated/integrated online MRIdian
TPS (1).
Next, on both platforms, the original contours are
automatically propagated to the daily image using rigid
(preferred for targets, when possible) and/or deformable
registration. Physicians and therapists then edit the contours as
needed to match the daily anatomy. To save time in contouring,
contour adjustments for SBRT plans may focus on anatomy
within a 2–3cm ring around the PTV, which captures the high
dose fall-off region of interest for OAR sparing and has been
shown to be sufficient for robust and fast plan re-optimization
(48). Electron density is updated, either through contour-based
bulk density override (0.35 T system) or application of the
average electron density for each structure as identified from
the simulation image (1.5 T system). The plan is then
reoptimized, typically through an adjustment of beam
weighting, segments, and fluence or mix thereof, with
maintenance of the original beam angles. In both planning
systems, this process is rapid within the order of seconds to
several minutes (51, 98).
Online, pre-treatment quality assurance is then performed
(99), and the original plan is compared to the online adaptive
plan, with selection of the superior plan for delivery. It is key to
note that formal dosimetric (e.g. dose metric or DVH)
comparison should be used for the selection of the superior
plan, as visual assessment of the plan alone, for the need for daily
adaptation has been shown to be inadequate for identifying
fractions benefitting from plan change (100). The beam-on
component of ART on both MRgART systems utilizes real-
time cine MRI monitoring and beam-gating. On the 0.35 T
system, cine MR imaging is at a rate of eight frames per second
and beam-gating is automatic, through a deformable
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registration-based tracking algorithm (83). On the 1.5 T system,
beam-gating is presently manual but still based on real time MRI
target (or adjacent surrogate) monitoring (101). On both
systems, breath-hold delivery may improve efficiency of
treatment, and combinations of patient visual feedback and/or
audio respiratory coaching have been utilized successfully.
Specifics of motion management choices are discussed in more
depth in the Motion Management section.
DISCUSSION
In the future, MRgART is likely to increase in both complexity
and indication.
MR-only planning has been achieved in some settings (102)
and may find ready application in liver patients in the setting of
MRgRT. Future considerations also include personalized
adaptation or dose prescribing based on MRI-specific imaging
indications of tumor response, such as changes in diffusion
restriction (103) or MRI tumor volumes during the course of
treatment (104). However, standardization of imaging and
methods for signal detection, as well as application to patient
care, is needed for mainstream use (105). Ongoing and
additional prospective clinical trial efforts are needed to
establish the clinical benefit of MRgART in liver patients.
A future MRI-only liver SBRT workflow has advantages over
the aforementioned CT–MR hybrid workflow, with the
potential to improve overall efficiency. It requires replacement
of planning CT with synthetic CT generated from the planning
MRI (i.e. electron density mapping) through voxel-based
methods, atlas based methods, or hybrid approach (106). This
MRI-only workflow will reduce CT scanning to enable
reduction of radiation dose and imaging costs with more
efficient use of resources, and more importantly, avoid
geometric uncertainties of MRI–CT co-registration through
direct delineation of the target and OARs on MRI with
improved geometric treatment accuracy (107). Inter- and
intra-fractional treatment adaptation with fast auto-
contouring algorithms, automated treatment planning, and
automatic reconstruction of the delivered dose of the day
cumulative dose delivered would facilitate and improve the
accuracy of SBRT for liver cancer patients (108).
Several studies have demonstrated that higher doses of RT
were correlated with improvement of tumor control and overall
survival for many unresectable liver tumors (i.e. liver CRC
metastases and hepatobiliary tumors) (40, 93, 95, 109).
However the ability to deliver high-dose of RT to liver tumors
adjacent to nearby luminal gastrointestinal organs and the
requirement to spare sufficient un-involved liver to maintain
synthetic liver function necessitate accurate liver cancer target
delineation, precise RT planning, and real-time treatment
adaptation to improve sustained local control while reducing
the risk of toxicity. These challenges can be mitigated in part by
MRI-based RT planning and delivery, when personalized dose
escalation to liver tumors could be based on cumulative delivered
doses to limiting OAR, rather than limiting the RT dose based on
a single pre-treatment image.
MRgRT provides an elegant platform to investigate early
biomarkers for tumor control and late toxicity, through
repeated MR functional imaging obtained throughout a course
of radiation therapy. DWI MRI is based upon differences in
mobility of water protons in tissues and is useful for detection
and characterization of focal liver lesion and assessment of tumor
response to treatment. Advanced diffusion methods such as
intravoxel incoherent motion (IVIM) may have potential for
detection, staging, and evaluation of the progression of liver
fibrosis and for liver lesion characterization (110). DWI has been
studied as a potential imaging biomarker early during SBRT
associated with long term local control. It has also been
investigated as a biomarker for radiation related liver injury
(103). Previous work has shown heterogeneous cell populations
within individual tumors, and repeat DCE MRI scans
throughout treatment were able to predict the change in
hypoxia in preclinical model (111) Employing pre- and intra-
treatment functional imaging provides an opportunity for
further personalized treatment with optimization of SBRT dose
on a daily basis to accommodate temporal heterogeneities in
tumor, where SBRT dose escalation could target areas of highest
biological resistance, while areas of good response undergo dose
de-escalation, opening avenues for dose adaptation with
improved therapeutic ratio.
Radiomics aims to utilize computational pipelines to extract
the most informative features from radiological images routinely
acquired in clinical settings. Recent computational advances have
allowed deep neural networks (DNNs) to learn unique features
with unprecedented performance for image classification (112),
eliminating the need for hand-engineered features required for
“conventional” radiomics analyses. The application of deep
learning in the medical imaging field is in its infancy (112),
with only a few studies that have applied DNN radiomics
pipelines to predict patients’ clinical outcomes (113–119). The
plethora of MR images generated through an MRgRT
radiotherapy system would create very large datasets capable of
similar, if not improved, utility given the more visualization
provided by MRI. The use of MRI-derived data combined with
correlative biologic factors (e.g. genomics, metabolomics) and
tumor microenvironment information will provide more
understanding of tumor biology, implicating heterogeneous
tumor subpopulations and their surrounding microenvironment
as key factors in clinical outcomes and allow for a substantial
degree of treatment personalization.
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